AIM: To investigate whether protein expression or cellular localisation of P-cadherin is associated with clinicopathological characteristics in benign and @entity1489 . EXPERIMENTAL DESIGN: P-cadherin expression and the Ki-67 labelling index were analysed immunohistochemically by using @entity3145 ( @entity3145 ). Membranous and cytoplasmic expression was scored semiquantitatively (0 to 2+). RESULTS: P-cadherin protein expression of any intensity (1+ to 2+) was detected in the membrane in 41.5% (132/318) and in the cytoplasm in 64.2% (204/318) of @entity1 . In general, P-cadherin expression was significantly reduced in @entity320 (p<0.001) and @entity320 metastases (p<0.001), compared with benign nevi. Additionally, loss of membranous P-cadherin was associated with Clark level (p = 0.011) and @entity5 thickness (p<0.001). Interestingly, a significantly lower P-cadherin expression was shown by dermal nevi than by compound and junctional nevi (p = 0.005; p = 0.025). In primary @entity320 , a Ki-67 labelling index <5% was not associated with P-cadherin protein expression, suggesting that loss of P-cadherin expression was not associated with proliferation. None of the other clinical and histological factors analysed was significantly related to P-cadherin expression. Low cytoplasmic P-cadherin expression was associated with @entity5 recurrence (p = 0.03) in all the @entity1 who were analysed. After testing various multivariate Cox regression models, loss of cytoplasmic P-cadherin expression remained a highly significant adverse risk factor for @entity5 recurrence in @entity1 with @entity5 <2 mm. CONCLUSIONS: Loss of cytoplasmic P-cadherin expression is common in advanced @entity320 and can be a prognostic marker of progression in @entity1 with @entity320 , most useful in @entity1 with primary @entity5 <2 mm in thickness.

Prognostic relevance of P-cadherin expression in melanocytic XXXX analysed by high-throughput @entity3145 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3145 :: ('MESH:D017695', 'Disease') :: ['TMAs', 'tissue microarrays'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour'] @entity1489 :: ('MESH:D012878', 'Disease') :: ['malignant melanocytic skin tumours'] @entity320 :: ('MESH:D008545', 'Disease') :: ['melanoma', 'malignant melanomas', 'melanomas']
@entity1489 :: (MESH:D012878,Disease) :: ['skin tumours']
